Reza Mazhari is currently a Director in NIBR Strategic Alliances/BD&L. Reza has a strong experience in both business development and research and development, most recently from Rexahn Pharmaceuticals in Rockville, MD where he was Vice President, Translational Medicine and was responsible for both business development and translational medicine activities. Prior to Rexahn, Reza was at Cerecor, Inc. as VP of Drug Discovery and Development, joined the company at inception, where he also led early-stage in-licensing efforts (2011-2015), was a co-founder and VP, Research and Pharmacology at Cardioxyl Pharmaceuticals (2006-2011; acquired by BMS), and was Director, Cardiovascular Physiology at Artesian Therapeutics (2003-2005; acquired by Cardiome). Reza received his B.S. and Ph.D. in Bioengineering from the University of California, San Diego. He did his post-doctoral fellowship at the Johns Hopkins School of Medicine, and currently is a part-time adjunct assistant professor of Medicine.